

Table 8.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1999 to 2008
Recipients with Kidney-Pancreas Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	941	915	891	906	871	881	903	924	864	837
Tx with Antirejection Treatments	260	232	194	191	153	127	118	108	94	94
Antibodies										
Any in Category	42.3%	41.4%	32.0%	50.8%	58.2%	63.0%	50.8%	50.0%	51.1%	63.8%
Atgam/NRATG/NRATS	6.5%	3.9%	0.5%	2.6%	2.0%	3.1%	2.5%	2.8%	0.0%	1.1%
OKT3	24.6%	22.8%	12.4%	10.5%	9.8%	11.8%	11.0%	6.5%	9.6%	4.3%
Thymoglobulin	16.2%	15.1%	20.6%	34.0%	39.9%	44.1%	39.0%	35.2%	37.2%	50.0%
Zenapax	1.5%	1.7%	1.0%	4.7%	11.8%	7.1%	7.6%	9.3%	9.6%	10.6%
Simulect	0.4%	2.2%	0.5%	1.0%	1.3%	1.6%	0.0%	0.9%	0.0%	1.1%
Campath	0.0%	0.0%	0.0%	0.5%	3.9%	2.4%	0.0%	0.0%	2.1%	1.1%
Corticosteroids										
Any in Category	80.8%	82.8%	87.1%	76.4%	68.6%	68.5%	71.2%	68.5%	68.1%	52.1%
Steroids	80.8%	82.8%	87.1%	76.4%	68.6%	68.5%	71.2%	68.5%	68.1%	52.1%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.